Adding SGLT2 Cotransporter Inhibitor to PPARγ Activator Does Not Provide an Additive Effect in the Management of Diabetes-Induced Vascular Dysfunction
Article in Pharmacology (October 2023)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
Article in Biomedicines (July 2023)
SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI
Article in BMC Cardiovascular Disorders (June 2023)